Laboratorio Farmaceutico Erfo Past Earnings Performance
Past criteria checks 1/6
Laboratorio Farmaceutico Erfo's earnings have been declining at an average annual rate of -24.8%, while the Personal Products industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Farmaceutico Erfo's return on equity is 5.4%, and it has net margins of 7.6%.
Key information
-24.8%
Earnings growth rate
-31.3%
EPS growth rate
| Personal Products Industry Growth | 8.7% |
| Revenue growth rate | 9.1% |
| Return on equity | 5.4% |
| Net Margin | 7.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Laboratorio Farmaceutico Erfo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 6 | 0 | 1 | 0 |
| 31 Mar 24 | 6 | 1 | 1 | 0 |
| 31 Dec 23 | 6 | 1 | 1 | 0 |
| 30 Sep 23 | 6 | 1 | 1 | 0 |
| 30 Jun 23 | 5 | 1 | 1 | 0 |
| 31 Mar 23 | 5 | 1 | 1 | 0 |
| 31 Dec 22 | 5 | 1 | 1 | 0 |
| 30 Sep 22 | 5 | 1 | 1 | 0 |
| 30 Jun 22 | 5 | 1 | 1 | 0 |
| 31 Mar 22 | 5 | 1 | 1 | 0 |
| 31 Dec 21 | 5 | 1 | 1 | 0 |
| 31 Dec 20 | 4 | 1 | 1 | 0 |
| 31 Dec 19 | 5 | 1 | 1 | 0 |
| 31 Dec 18 | 4 | 1 | 1 | 0 |
Quality Earnings: RK7 has high quality earnings.
Growing Profit Margin: RK7's current net profit margins (7.6%) are lower than last year (12.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RK7's earnings have declined by 24.8% per year over the past 5 years.
Accelerating Growth: RK7's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RK7 had negative earnings growth (-34.9%) over the past year, making it difficult to compare to the Personal Products industry average (10.8%).
Return on Equity
High ROE: RK7's Return on Equity (5.4%) is considered low.